Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting June 3, 2024 at 8:00 AM EDT PDF Version -- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration [...]
Sessions, Posters and Abstracts in Uveal MelanomaThis year at ASCO 2024 was a bit more special, as it marks the 5-year anniversary of Kevin’s first contact with Loren and Melody at the ACIS Patient Advocacy Booth! In June 2019, Kevin was facing biopsy a few weeks later, and he didn’t know anything about the [...]
We are happy to report the incredible success of our inaugural "Lookin For A Cure" 5K event in Tampa, dedicated to raising awareness and funds for Ocular Melanoma research. Held on Sunday, March 24th, 2024, at Al Lopez Park, this event brought together [...]
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research Replimune Presents Updated Data on RP2 in Uveal Melanoma RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of [...]
FDA Approved Liver-Directed Treatment for Metastatic Ocular Melanoma Patients Delcath Systems announces a new locator on their treatment page for liver-directed treatment of metastatic ocular melanoma. Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System) Check this out and share with metastatic #ocularmelanoma patients. Please especially share the news if [...]
Novel Metastatic Treatment for Metastatic Ocular Melanoma Patients Looking for treatment options for metastatic ocular melanoma? IDEAYA BIOSCIENCES is currently enrolling patients in multiple arms for their clinical trials for metastatic ocular melanoma, as well as front line treatments. Check out their website, https://www.ideayabio.com/ for information on their enrolling trials. Additionally, you can [...]
Imagine a world where Ocular Melanoma, a daunting diagnosis, opens a door to hope rather than despair. In the forefront of this optimistic horizon stands Dr. Deborah Barton, alongside the innovative team at T-Scan Therapeutics, pioneering the path to revolutionary treatments. Today, we delve into their journey of discovery, where every breakthrough offers a [...]
Celebrating Life Beyond Ocular Melanoma: Tricia's 19-Year Journey In the spring of 2005, Tricia's routine eye examination uncovered something life-altering. At 46, a day that began with the simple intent to get reading glasses led to a diagnosis of ocular melanoma. Facing the unknown with her family by her side, Tricia's resilience shone [...]
A Cure in Sight attends the Melanoma Patient Exchange Forum, hosted by Melanoma research Alliance Washington DC, February 22, 2024—A Cure in Sight Ocular Melanoma has been in attendance at the Melanoma Exchange Patient Forum this week to advocate for awareness for ocular melanoma. This event is hosted by the Melanoma Research Alliance. [...]
ACIS announces new Director of Community Engagement: Jennifer Hoke to join ACIS’s growing team January 15 Raleigh, NC., January 15, 2024—A Cure in Sight Ocular Melanoma, today announced that they have expanded their Non-Profit foundation by hiring Jennifer Hoke as the Director of Community Engagement. Jennifer will be coordinating ACIS sponsored communications and [...]
